Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04141865 · ClinicalTrials.gov registry record
Effect of Xen Implantation on the Aqueous Humor Proteome
A clinical trial, sponsored by Price Vision Group.
- Terminated
- Registry status
- 3
- Enrollment target
NCT04141865: Clinical Trial study, sponsored by Price Vision Group.
NCT04141865 is a clinical trial that was terminated before completion, run by Price Vision Group. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04141865 was terminated before completion, sponsored by Price Vision Group.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how the aqueous humor proteome changes after implantation of a Xen microstent for treatment of glaucoma.
Primary Outcome
The aqueous humor proteome will be assessed with liquid chromotography/mass spectometry (quantitative LC-MS/MS).
Interventions
- DEVICE Xen
- DEVICE Aqueous shunt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-10-24 |
| Est. Completion | 2022-02-15 |
Why NCT04141865 stopped before completion
NCT04141865 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Xen is the first listed.
NCT04141865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04141865 about?
NCT04141865 is a clinical study titled "Effect of Xen Implantation on the Aqueous Humor Proteome". The purpose of this study is to determine how the aqueous humor proteome changes after implantation of a Xen microstent for treatment of glaucoma.
What is the current status of trial NCT04141865?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2019-10-24. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT04141865?
The interventions under investigation include: Xen (DEVICE), Aqueous shunt (DEVICE).
Who is sponsoring clinical trial NCT04141865?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI